ADA Standards of Care update reflects new data on CV, kidney disease in type 2 diabetes


Disclosures: Gabbay is chief scientific and medical officer at the ADA.

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The American Diabetes Association announced updates to its 2022 Standards of Medical Care in Diabetes to reflect new data on cardiovascular outcomes with diabetes and kidney disease and use of SGLT2 inhibitors.

Robert Gabby

The updates, published as annotations in the Living Standards of Care, include new data on CV outcomes in adults with type 2 diabetes and kidney disease using finerenone (Kerendia, Bayer), the impact of SGLT2 inhibitors on heart failure and renal outcomes in people with type 2 diabetes and the latest information on calculating estimated glomerular filtration rate and the inclusion of race for kidney disease diagnosis.

Diabetes Words 2019
Source: Adobe Stock

“This is the fifth year that we are able to update the Standards of Care after it has been published through our Living Standards of Care updates, making it possible to give diabetes care providers the most important information and the latest evidence relevant to their practice, ” Robert Gabbay, MD, chief scientific and medical officer for the ADA, said in a press release. “With approximately 537 million adults living with diabetes around the world, it’s important to equip providers with the latest research through our guidelines as we learn more.”

As Healio previously reported, the ADA’s 2022 Standards of Care were published in January. The standards included new recommendations on first-line diabetes therapy and comorbidities, diabetes screening for adults and gestational diabetes testing.

Updates to the 2022 Standards of Care include information added to the following sections:

  • Section 10. Cardiovascular Disease and Risk Management has been updated to include evidence from multiple trials on the impact of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), dapagliflozin (Farxiga, AstraZeneca) and finerenone on CV outcomes in type 2 diabetes. The updates included evidence from EMPEROR-Preserved, PRESERVED-HF, FIDELIO-DKD and FIGARO-DKD trials.
  • Section 11. Chronic Kidney Disease and Risk Mmanagement has been updated to include evidence from EMPEROR-Preserved, FIDELIO-DKD and FIGARO-DKD on renal outcomes in adults with type 2 diabetes. The update also includes new recommendations from the National Kidney Foundation and the American Society of Nephrology Task Force on reassessing the inclusion of race in diagnosing kidney disease.

Since 2018, the ADA had issued updates to its Standards of Care throughout the year with annotations for new evidence or regulatory changes that merit immediate incorporation. The changes are incorporated into the online version of the Standards of Care as they are approved throughout the year,
The complete, annotated Standards of Care can be accessed online at diabetes care. The Abridged Standards of Medical Care in Diabetes have also been updated and can be accessed online at Clinical diabetes.

Related Posts